Early Detection Research Network

Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection

CD90/THY1 is overexpressed by tumor-associated stromal cells as scored by immunohistochemistry, RT-PCR analysis of laser-capture microdissected cells. CD90 protein is detected by quantitative glycopeptide-capture proteomics in tissue digestion media preparations, and also by Western blotting. CD90 protein is detected in urine. The goal is to determine if urinary CD90 level can be used to detect cancer.

There are currently no items in this folder.